Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation

Transplantation

Volumn 93, Issue 11, 2012, Pages 1101-1107

  Rusai, Krisztina ^a   Schmaderer, Christoph ^a   Baumann, Marcus ^a   Chmielewski, Stefan ^a   Prókai, Ágnes ^b   Kis, Eva ^b   Szabó, Attila J ^b   Leban, Johann ^c   Doblhofer, Robert ^c   Ammendola, Aldo ^c   Lutz, Jens ^a   Heemann, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c 4SC AG   (Germany)

Author keywords

Acute rejection; Kidney; Novel dihydroorotate dehydrogenase inhibitor

Indexed keywords

CD3 ANTIGEN; CD5 ANTIGEN; CD68 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; MESSENGER RNA; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; VIDOFLUDIMUS;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN NORWAY RAT; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GLOMERULOSCLEROSIS; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LEWIS RAT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SURVIVAL RATE; SURVIVAL TIME; TUBULITIS;

ANIMALS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; DICARBOXYLIC ACIDS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FIBROSIS; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; POSTOPERATIVE COMPLICATIONS; PROTEINURIA; RATS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862299279     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824fd861     Document Type: Article

References (32)

1. Weir MR, Wali RK. Minimizing the risk of chronic allograft nephropathy. Transplantation 2009; 87: 14-8.
2. Wu O, Levy AR, Briggs A, et al. Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation 2009; 87: 1330Y9. Review.
3. Pinto P, Dougados M. Leflunomide in clinical practice. Acta Reumatol Port 2006; 31: 215-24.
4. Xiao F, Chong AS, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 828Y34. (Pubitemid 24329188)
5. Kyles AE, Gregory CR, Griffey SM, et al. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation 2003; 75: 1128Y33. (Pubitemid 36513008)
6. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-82. (Pubitemid 34260577)
7. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717Y22. (Pubitemid 24206409)
8. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-66. (Pubitemid 34174284)
9. Liacini A, Seamone ME, Muruve DA, et al. AntiYBK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90: 1450-7.
10. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004; 77: 1460Y1. (Pubitemid 38668445)
11. Leca N. Leflunomide use in renal transplantation. Curr Opin Organ Transplant 2009; 14: 370Y4.
12. Pan F, Ebbs A, Wynn C, et al. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation 2003; 75: 1110Y4. (Pubitemid 36513004)
13. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8: 1972-81.
14. Leban J, Kralik M, Mies J, et al. SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors. Bioorg Med Chem Lett 2005; 15: 4854-4857. (Pubitemid 41354821)
15. Fitzpatrick LR, Deml L, Hofmann C, et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1763-77.
16. Kulkarni OP, Sayyed SG, Kantner C, et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol 2010; 176: 2840-7.
17. Loverre A, Tataranni T, Castellano G, et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibodymediated rejection. Am J Transplant 2011; 11: 1248-59.
18. Tang JL, Subbotin VM, Antonysamy MA, et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72: 348Y50. (Pubitemid 32729364)
19. Gorbacheva V, Fan R, Li X, et al. Interleukin-17 promotes early allograft inflammation. Am J Pathol 2010; 177: 1265-73.
20. Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322Y32.
21. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15. (Pubitemid 351149996)
22. Hamar P, Peti-Peterdi J, Rázga Z, et al. Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney. J Am Soc Nephrol 1999; 10(suppl 11): S234-8. (Pubitemid 29038194)
23. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495Y508. (Pubitemid 27469555)
24. Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 2002; 227: 53-8.
25. Lutz J, Huang H, Deng M, et al. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation 2007; 83: 741-6. (Pubitemid 46569192)
26. Kim JY, Lim SW, Li C, et al. Effect of FTY720 on chronic cyclosporine nephropathy in rats. Transplantation 2005; 80: 1323Y3023.
27. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
28. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010; 106: 1646-55.
29. Booth AJ, Bishop DK. TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2010; 2: 511-20.
30. Feng W, Li W, Liu W, et al. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenolinduced heart failure. Exp Mol Pathol 2009; 87: 212-8.
31. Simonian PL, Roark CL, Wehrmann F, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 2009; 182: 657-65.
32. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)